Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Heart and Vessels
Published in: Heart and Vessels 11/2020

Open Access 01-11-2020 | Heart Transplantation | Original Article

Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics

Authors: Salaheldin Ahmed, Abdulla Ahmed, Habib Bouzina, Jakob Lundgren, Göran Rådegran

Published in: Heart and Vessels | Issue 11/2020

Login to get access

Abstract

Background

The prevalence of heart failure (HF) is rising with ageing population and constitutes a major health problem globally. A common complication of HF is pulmonary hypertension (PH) which negatively impacts survival. A pathophysiological association between HF and PH with tumorigenic processes has been suggested. We aimed to identify the plasma levels of, and the association between tumour-related proteins and hemodynamic improvements in patients with HF and PH due to left heart disease (LHD) before and 1-year after heart transplantation (HT).

Methods

Forty-eight tumour-related proteins were measured with proximity extension assay in plasma from 20 controls and 26 HF patients before and 1-year after HT. Patients’ hemodynamics were measured with right heart catheterization.

Results

Out of 48 proteins, specifically, plasma levels of endocan and brother of CDO (BOC) were elevated in end-stage HF patients compared to controls (p < 0.001), but decreased after HT (p < 0.01), towards controls’ levels. The decrease of endocan levels after HT correlated with improved mean pulmonary arterial pressure (rs = 0.80, p < 0.0001), pulmonary arterial wedge pressure (rs = 0.63, p = 0.0012), and pulmonary vascular resistance (rs = 0.70, p < 0.001). The decrease and normalization of BOC after HT correlated with decreased mean right atrial pressure (rs = 0.61 p = 0.0015) and NT-proBNP (rs = 0.57, p = 0.0022), as well as increased cardiac index (rs = − 0.51, p = 0.0086) and left-ventricular stroke work index (rs = − 0.57, p = 0.0039).

Conclusion

Our results suggest that (i) plasma endocan in HF may reflect the state of pulmonary vascular congestion and PH-LHD, whereas (ii) plasma BOC may reflect the cardiac function and the hemodynamic overload in HF. The exact role of these proteins and their clinical applicability as biomarkers in HF and PH-LHD ought to be investigated in larger cohorts.
Appendix
Available only for authorised users
Literature
1.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200PubMed
2.
Heggermont WA, Papageorgiou A-P, Heymans S, van Bilsen M (2016) Metabolic support for the heart: complementary therapy for heart failure? Eur J Heart Fail 18:1420–1429PubMed
3.
Vachiéry J-L, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs JSR, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62:D100–D108PubMed
4.
Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, Gomberg-Maitland M, Murali S, Frantz RP, McGlothlin D, Horn EM, Benza RL (2012) World Health Organization Pulmonary Hypertension Group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 31:913–933PubMed
5.
Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148–2159PubMed
6.
Ibrahim NE, Januzzi JL (2017) Beyond natriuretic peptides for diagnosis and management of heart failure. Clin Chem 63:211–222PubMed
7.
Magnussen C, Blankenberg S (2018) Biomarkers for heart failure: small molecules with high clinical relevance. J Intern Med 283:530–543PubMed
8.
Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M (2019) Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 53:1801887PubMedPubMedCentral
9.
Ibrahim NE, Januzzi JL Jr (2018) Established and emerging roles of biomarkers in heart failure. Circ Res 123:614–629PubMed
10.
Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, ESC Scientific Document Group (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119PubMed
11.
Sakamoto M, Hasegawa T, Asakura M, Kanzaki H, Takahama H, Amaki M, Mochizuki N, Anzai T, Hamasaki T, Kitakaze M (2017) Does the pathophysiology of heart failure prime the incidence of cancer? Hypertens Res 40:831–836PubMed
12.
Hasin T, Gerber Y, McNallan SM, Weston SA, Kushwaha SS, Nelson TJ, Cerhan JR, Roger VL (2013) Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol 62:881–886PubMedPubMedCentral
13.
Chen Z, Liu M, Li L, Chen L (2018) Involvement of the Warburg effect in non-tumor diseases processes. J Cell Physiol 233:2839–2849PubMed
14.
Du Bois D, Du Bois EF (1916) Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863–871
15.
Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S (2017) The cancer theory of pulmonary arterial hypertension. Pulm Circ 7(2):285–299PubMedPubMedCentral
16.
Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF, Ishizaki T (2011) p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol 300:L753–L761PubMed
17.
Mouraret N, Marcos E, Abid S, Gary-Bobo G, Saker M, Houssaini A, Dubois-Rande JL, Boyer L, Boczkowski J, Derumeaux G, Amsellem V, Adnot S (2013) Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension. Circulation 127:1664–1676PubMedPubMedCentral
18.
Li KHC, Gong M, Li G, Baranchuk A, Liu T, Wong MCS, Jesuthasan A, Lai RWC, Lai JCL, Lee APW, Bayes-Genis A, de la Espriella R, Sanchis J, Wu WKK, Tse G, Nunez J (2018) Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia 10(2):e011044PubMedPubMedCentral
19.
Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, Dobbels F, Kirk R, Rahmel AO, Yusen RD, Stehlik J (2013) The registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report—2013; focus theme: age. J Heart Lung Transplant 32:951–964PubMed
20.
Ahmed S, Ahmed A, Säleby J, Bouzina H, Lundgren J, Rådegran G (2020) Elevated plasma tyrosine kinases VEGF-D and HER4 in heart failure patients decrease after heart transplantation in association with improved haemodynamics. Heart Vessels 35:786–799PubMedPubMedCentral
21.
Ahmed A, Ahmed S, Arvidsson M, Bouzina H, Lundgren J, Rådegran G (2020) Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics. ESC Heart Failure 7:223–234PubMed
22.
Assarsson E, Lundberg M, Holmquist G, Björkesten J, Bucht Thorsen S, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, Andersson AC, Lindstedt P, Stenvang J, Gullberg M, Fredriksson S (2014) Homogenous 96-Plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9:e95192PubMedPubMedCentral
23.
Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacsi P, Augustine S, Aaronson K, Barr M (2006) Listing criteria for heart transplantation: international society for heart and lung transplantation guidelines for the care of cardiac transplant candidates—2006. J Heart Lung Transplant 25:1024–1042PubMed
24.
Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EAM, Zuckermann A (2016) The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 35:1–23PubMed
25.
Benjamini Y, Krieger AM, Yekutieli D (2006) Adaptive linear step-up procedures that control the false discovery rate. Biometrika 93:491–507
26.
Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, Wei W, Wang Y (2012) Expression and distribution of endocan in human tissues. Biotech Histochem 87:172–178PubMed
27.
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A (2015) Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis 243:339–343PubMed
28.
Bălănescu P, Lădaru A, Bălănescu E, Voiosu T, Băicuş C, Dan GA (2016) Endocan, novel potential biomarker for systemic sclerosis: results of a pilot study. J Clin Lab Anal 30:368–373PubMed
29.
Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel A-B, Lassalle P (2006) Endocan, a new endothelial marker in human sepsis*. Crit Care Med 34:532–537PubMed
30.
Wang X-s, Yang W, Luo T, Wang J-m, Jing Y-y (2015) Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomark 19:124–127
31.
Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte J-J, Copin M-C, Tonnel A-B, Lassalle P (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12:4575PubMed
32.
Van Linthout S, Tschöpe C (2017) Inflammation—cause or consequence of heart failure or both? Curr Heart Fail Rep 14:251–265PubMedPubMedCentral
33.
Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J (2012) Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 60:1455–1469PubMed
34.
Breitling S, Ravindran K, Goldenberg NM, Kuebler WM (2015) The pathophysiology of pulmonary hypertension in left heart disease. Am J Physiol Lung Cell Mol Physiol 309:L924–L941PubMed
35.
Kosir G, Jug B, Novakovic M, Mijovski MB, Ksela J (2019) Endocan is an independent predictor of heart failure-related mortality and hospitalizations in patients with chronic stable heart failure. Dis Mark 2019:9134096
36.
Zhao H, Xue Y, Guo Y, Sun Y, Liu D, Wang X (2017) Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension. Int Immunopharmacol 42:115–121PubMed
37.
Petrova R, Joyner AL (2014) Roles for Hedgehog signaling in adult organ homeostasis and repair. Development 141:3445–3457PubMedPubMedCentral
38.
Yao E, Chuang P-T (2015) Hedgehog signaling: from basic research to clinical applications. J Formos Med Assoc 114(7):569–576PubMed
39.
Lavine KJ, Kovacs A, Ornitz DM (2008) Hedgehog signaling is critical for maintenance of the adult coronary vasculature in mice. J Clin Invest 118(7):2404–2414PubMedPubMedCentral
40.
Kusano KF, Pola R, Murayama T, Curry C, Kawamoto A, Iwakura A, Shintani S, Ii M, Asai J, Tkebuchava T, Thorne T, Takenaka H, Aikawa R, Goukassian D, von Samson P, Hamada H, Yoon Y-S, Silver M, Eaton E, Ma H, Heyd L, Kearney M, Munger W, Porter JA, Kishore R, Losordo DW (2005) Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med 11(11):1197–1204PubMed
41.
Fricker LD (1988) Carboxypeptidase E. Annu Rev Physiol 50:309–321PubMed
42.
Cawley NX, Wetsel WC, Murthy SRK, Park JJ, Pacak K, Loh YP (2012) New roles of carboxypeptidase E in endocrine and neural function and cancer. Endocr Rev 33(2):216–253PubMedPubMedCentral
43.
Lynch DR, Venable JC, Snyder SH (1988) Enkephalin convertase in the heart: similar disposition to atrial natriuretic factor. Endocrinology 122(6):2683–2691PubMed
44.
Jia E-Z, Wang J, Yang Z-J, Zhu T-B, Wang L-S, Wang H, Li C-J, Chen BO, Cao K-J, Huang J, Ma W-Z (2009) Association of the mutation for the human carboxypeptidase E gene exon 4 with the severity of coronary artery atherosclerosis. Mol Biol Rep 36(2):245–254PubMed
45.
Wang J, Zhang Y, Yang Z-J, Zhu T-b, Wang L-s, Chen B, Cao K-j, Huang J, Ma W-z, Jia E-z (2008) Association of human carboxypeptidase E exon5 gene polymorphisms with angiographical characteristics of coronary atherosclerosis in a Chinese population. Acta Pharmacol Sin 29:736–744PubMed
46.
Jia E-Z, Wang J, Yang Z-J, Zhu T-B, Wang L-S, Chen BO, Cao K-J, Huang J, Ma W-Z (2008) Molecular scanning of the human carboxypeptidase E gene for mutations in Chinese subjects with coronary atherosclerosis. Mol Cell Biochem 307(1–2):31–39PubMed
47.
Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N (2002) Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 62:295–300PubMed
48.
Unal D, Tasdemir A, Oguz A, Eroglu C, Cihan YB, Turak EE, Karaman H, Soyuer S (2013) Is human kallikrein-11 in gastric cancer treated with surgery and adjuvant chemoradiotherapy associated with survival? Pathol Res Pract 209:779–783PubMed
49.
Luo L-Y, Shan SJC, Elliott MB, Soosaipillai A, Diamandis EP (2006) Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. Clin Cancer Res 12:742–750PubMed
50.
Wei C-C, Chen Y, Powell LC, Zheng J, Shi K, Bradley WE, Powell PC, Ahmad S, Ferrario CM, Dell'Italia LJ (2012) Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. PLoS ONE 7:e40110PubMedPubMedCentral
51.
Sano A, Sangai T, Maeda H, Nakamura M, Hasebe T, Ochiai A (2007) Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int J Oncol 30:1493–1498PubMed
52.
Hoeflich A, David R, Hjortebjerg R (2018) Current IGFBP-related biomarker research in cardiovascular disease-we need more structural and functional information in clinical studies. Front Endocrinol (Lausanne) 9:388
53.
Pucci A, Zanini C, Granata R, Ghignone R, Iavarone A, Broglio F, Sorrentino P, Bergamasco L, Rinaldi M, Ghigo E (2009) Myocardial insulin-like growth factor-1 and insulin-like growth factor binding protein-3 gene expression in failing hearts harvested from patients undergoing cardiac transplantation. J Heart Lung Transplant 28:402–405PubMed
54.
Lee W-S, Kim J (2018) Insulin-like growth factor-1 signaling in cardiac aging. Biochim Biophys Acta Mol Basis Dis 1864:1931–1938PubMed
55.
Chisalita SI, Dahlström U, Arnqvist HJ, Alehagen U (2011) Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors. Eur J Endocrinol 165:891–898PubMed
56.
Wang Y, Chen Y, Yan Y, Li X, Chen G, He N, Shen S, Chen G, Zhang C, Liao W, Liao Y, Bin J (2016) Loss of CEACAM1, a tumor-associated factor, attenuates post-infarction cardiac remodeling by inhibiting apoptosis. Sci Rep 6:21972PubMedPubMedCentral
57.
Hjalmarson Å, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus K-L, Jánosi A, Thorgeirsson G, Dunselman PHJM, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P, Group ftM-HS (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 283:1295–1302PubMed
58.
López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Pedersen CT, Members TF (2004) Expert consensus document on angiotensin-converting enzyme inhibitors in cardiovascular disease: the Task Force on ACE inhibitors of the European Society of Cardiology. Eur Heart J 25:1454–1470PubMed
59.
Silva IVG, de Figueiredo RC, Rios DRA (2019) Effect of different classes of antihypertensive drugs on endothelial function and inflammation. Int J Mol Sci 20(14):3458PubMedCentral
60.
Shing CM, Fassett RG, Brown L, Coombes JS (2012) The effects of immunosuppressants on vascular function, systemic oxidative stress and inflammation in rats. Transpl Int 25:337–346PubMed
61.
Fréguin-Bouilland C, Godin M, Bellien J, Richard V, Remy-Jouet I, Dautreaux B, Henry J-P, Compagnon P, Thuillez C, Plissonnier D, Joannidès R (2011) Protective effect of mycophenolate mofetil on endothelial function in an aortic allograft model. Transplantation 91(1):35–41PubMed
62.
Nyman U, Grubb A, Larsson A, Hansson LO, Flodin M, Nordin G, Lindström V, Björk J (2014) The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clin Chem Lab Med 52:815–824PubMed
Metadata
Title
Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics
Authors
Salaheldin Ahmed
Abdulla Ahmed
Habib Bouzina
Jakob Lundgren
Göran Rådegran
Publication date
01-11-2020

Other articles of this Issue 11/2020

Heart and Vessels 11/2020 Go to the issue

Original Article

Permanent pacemaker implantation and its predictors in patients admitted for complete atrioventricular block: a report from the Tokyo Cardiovascular Care Unit Network multi-center registry

Original Article

Defining heterogeneity of epicardial functional stenosis with low coronary flow reserve by unsupervised machine learning

Letter

Reply to the letter by Dr. Rao: Role of palliative balloon pulmonary valvuloplasty in babies with tetralogy of Fallot

Original Article

Clinical feasibility of resting full-cycle ratio as a unique non-hyperemic index of invasive functional lesion assessment

Original Article

Randomized controlled trial of landiolol, a short-acting beta-1 adrenergic receptor blocker, illustrating changes in high-molecular weight adiponectin levels after elective percutaneous coronary intervention

Original Article

The effect of multiple-inflation balloon aortic valvuloplasty

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits